ID   MCAS
AC   CVCL_3020
DR   CLO; CLO_0037094
DR   EFO; EFO_0006453
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioGRID_ORCS_Cell_line; 557
DR   BioSample; SAMN03472857
DR   BioSample; SAMN10988206
DR   cancercelllines; CVCL_3020
DR   Cell_Model_Passport; SIDM00008
DR   CGH-DB; 343-2
DR   CGH-DB; 9356-4
DR   Cosmic; 849612
DR   Cosmic; 931362
DR   Cosmic; 948290
DR   Cosmic; 1240171
DR   Cosmic; 1707559
DR   Cosmic; 2429301
DR   Cosmic; 2582802
DR   Cosmic; 2674701
DR   DepMap; ACH-000796
DR   EGA; EGAS00001000610
DR   GDSC; 1240171
DR   GEO; GSM659382
DR   GEO; GSM827228
DR   GEO; GSM851924
DR   GEO; GSM887290
DR   GEO; GSM888365
DR   GEO; GSM1340583
DR   JCRB; JCRB0240
DR   LiGeA; CCLE_290
DR   LINCS_LDP; LCL-1493
DR   PharmacoDB; MCAS_888_2019
DR   Progenetix; CVCL_3020
DR   TKG; TKG 0662
DR   Wikidata; Q54904241
RX   PubMed=4056530;
RX   PubMed=9290701;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=17671176;
RX   PubMed=20215515;
RX   PubMed=22246397;
RX   PubMed=22460905;
RX   PubMed=22710073;
RX   PubMed=23839242;
RX   PubMed=24023729;
RX   PubMed=25485619;
RX   PubMed=25846456;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 27 hours (PubMed=4056530); ~28 hours (Note=Lot 03262008), ~20 hours (Note=Lot 01202012), ~39 hours (Note=Lot 08162016) (JCRB=JCRB0240).
CC   HLA typing: A*02:06,24:02; B*40:02,46:01; C*01:02,03:05; DQA1*02:01,03:02; DRB1*03:01,14:82 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=25846456; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=25846456; DepMap).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser504Arg (c.1512T>A); Zygosity=Unspecified (PubMed=25846456).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=78.1%; East Asian, South=21.89%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): JCRB; PubMed=22710073; PubMed=25877200; PubMed=30485824; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,12
ST   D16S539: 12
ST   D18S51: 15
ST   D19S433: 14.2,15
ST   D21S11: 29,31
ST   D2S1338: 19,25
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 8,11
ST   D8S1179: 11,12
ST   FGA: 18,21
ST   Penta D: 10,12
ST   Penta E: 16
ST   TH01: 6,8
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C4026; Ovarian mucinous cystadenocarcinoma
DI   ORDO; Orphanet_398961; Mucinous adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 36
//
RX   PubMed=4056530;
RA   Kidera Y., Yoshimura T., Ohkuma Y., Iwasaka T., Sugimori H.;
RT   "Establishment and characterization of a cell line derived from
RT   mucinous cystadenocarcinoma of human ovary.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 37:1820-1824(1985).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22246397; DOI=10.3892/or.2012.1626;
RA   Sato N., Saga Y., Mizukami H., Wang D., Fujiwara H., Takei Y.,
RA   Machida S., Ozawa K., Suzuki M.;
RT   "Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor
RT   cells lacking KRAS gene mutations.";
RL   Oncol. Rep. 27:1336-1340(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25846456; DOI=10.3892/ijo.2015.2951;
RA   Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M.,
RA   Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.;
RT   "Profiling of actionable gene alterations in ovarian cancer by
RT   targeted deep sequencing.";
RL   Int. J. Oncol. 46:2389-2398(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//